<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04195243</url>
  </required_header>
  <id_info>
    <org_study_id>CUCS-INTEC-MV-HADES-001</org_study_id>
    <nct_id>NCT04195243</nct_id>
  </id_info>
  <brief_title>Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus</brief_title>
  <official_title>Acute Effect of Dapagliflozin vs Empagliflozin Administration on Flow Mediated Dilation in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Universitario de Ciencias de la Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Universitario de Ciencias de la Salud, Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes mellitus (T2DM) is a considered one of the main global health challenges; the&#xD;
      vascular endothelium plays an important role in vascular dysfunction in DM; Hyperglycemia&#xD;
      induced by it is recognized as the main factor for the development of vascular complications&#xD;
      of the disease, secondary to a reduction in nitric oxide production; &quot;flow-mediated dilation&quot;&#xD;
      is the most commonly used technique for the evaluation of endothelial function, being the&#xD;
      non-invasive method most widely used. It has been reported that with the use of SGLT2&#xD;
      inhibitors the development of cardiovascular complications in patients with T2DM is a&#xD;
      decrease, as well the arterial stiffness, endothelial dysfunction and increasing on the shear&#xD;
      stress and blood viscosity; and experimentally.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study, is to evaluate the acute effect of the administration of&#xD;
      dapagliflozin in comparison with the administration of empagliflozin on endothelial&#xD;
      disfunction in individuals with T2DM; we will conduct a double-blind, randomized,&#xD;
      placebo-controlled, trial with 3 groups, each group of 24 male and female patients, between&#xD;
      40-65 years of age with T2DM, without hypertension, treated with insulins or thiazide&#xD;
      diuretics. Randomization will determine who will receive the intervention during 7-days trial&#xD;
      (Empagliflozin 25 mg 1 time daily 5 minutes or Dapagliflozin 10 mg before the first bite of&#xD;
      each meal or approved placebo capsules), the patients will also continue with their usual&#xD;
      treatment. The clinical findings and laboratory test and laboratory test include a metabolic&#xD;
      profile and biosafety, baseline and at 7 days. Body weight, body fat, body mass index (BMI)&#xD;
      and blood pressure will be determined during the initial and final visit, likewise,&#xD;
      hemodynamics parameters of endothelial disfunction by flow mediate dilation with a&#xD;
      high-resolution UNEX EF38G® ultrasound. Adverse events to treatment will be documented.&#xD;
      Statistical analysis: Mann-Whitney U Test and Wilcoxon exact test. A p &lt;0.05 will be&#xD;
      considered statistically significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 29, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow Mediated Dilation</measure>
    <time_frame>7 days</time_frame>
    <description>Change from baseline Flow mediated dilation at 7 days. Using a high-resolution UNEX EF38G ultrasound®, in a room at 22°C, with the patient lying supine, and the right arm extended</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose</measure>
    <time_frame>7 days</time_frame>
    <description>Before and after intervention, using the BioSystems® Glucose Oxidase / Peroxidase kit; in an automated clinical chemistry analysis equipment brand XL-100Erba</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>7 days</time_frame>
    <description>Before and after intervention, using the BioSystems® Glucose Oxidase / Peroxidase kit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>7 days</time_frame>
    <description>Before and after intervention, using the BioSystems® Glycerol phosphate Oxidase / Peroxidase kit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-density lipoprotein cholesterol</measure>
    <time_frame>7 days</time_frame>
    <description>Before and after intervention, using the BioSystems® Direct / Detergent HDL kit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low-density lipoprotein cholesterol</measure>
    <time_frame>7 days</time_frame>
    <description>Before and after intervention using the BioSystems® Cholesterol Oxidase / Peroxidase kit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>7 days</time_frame>
    <description>Before and after intervention the BioSystems® kit Modified Jaffe's no deproteinization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>7 days</time_frame>
    <description>Before and after intervention using an OMRON calibrated electronic digital sphygmomanometer model HEM 907 XL will be used. The patient will remain seated in a chair resting his back on the backrest, with a minimum rest of 5 minutes, The average of 3 measurements such as BP will be taken</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.&#xD;
Dapagliflozin capsules, 10 mg 1 time daily 5 minutes before the first meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.&#xD;
Empagliflozin capsules, 25 mg 1 time daily 5 minutes before the first meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.&#xD;
Dapagliflozin capsules, 400 mg 1 time daily 5 minutes before the first meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin Pill</intervention_name>
    <description>The patient will take one pill, every 24 hr, during 7 days</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <other_name>Forxiga</other_name>
    <other_name>Dapagliflozin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin Pill</intervention_name>
    <description>The patient will take one pill, every 24 hr, during 7 days</description>
    <arm_group_label>Empagliflozin</arm_group_label>
    <other_name>Jardiance</other_name>
    <other_name>Empagliflozin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pill</intervention_name>
    <description>The patient will take one pill, every 24 hr, during 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Calcined magnesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of T2DM&#xD;
&#xD;
          -  HbA1c &gt; 7 y &lt; 10&#xD;
&#xD;
          -  BMI 25 - 34.9 kg/m2&#xD;
&#xD;
          -  Signature of consent under information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypertension&#xD;
&#xD;
          -  Treated with insulin and / or loop diuretics and thiazides&#xD;
&#xD;
          -  T1DM&#xD;
&#xD;
          -  Hypotension&#xD;
&#xD;
          -  With any autoimmune disease&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Women who do not have a safe method of contraception&#xD;
&#xD;
          -  Women who are taking oral contraceptives or under treatment with hormone replacement&#xD;
             therapy&#xD;
&#xD;
          -  Woman pregnant or breastfeeding&#xD;
&#xD;
          -  Untreated thyroid disease&#xD;
&#xD;
          -  Patients with a cardiovascular disease that contraindicates the use of this&#xD;
             pharmacological class&#xD;
&#xD;
          -  Glomerular filtration rate &lt;60ml/min (Cockcroft-Gault)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Grover Paez, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Experimental and Clinical Therapeutics (INTEC), CUCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fernando Grover Paez, PhD</last_name>
    <phone>(33) 10585200</phone>
    <phone_ext>34215</phone_ext>
    <email>fgroverp@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Fernando Grover Paez, PhD</last_name>
      <phone>(33) 10585200</phone>
      <phone_ext>34215</phone_ext>
      <email>fgroverp@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Fernando Grover Paez, PhD</last_name>
      <phone>(33) 10585200</phone>
      <phone_ext>34215</phone_ext>
      <email>rballezaa@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Universitario de Ciencias de la Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Fernando Grover Paez</investigator_full_name>
    <investigator_title>Investigador Principal</investigator_title>
  </responsible_party>
  <keyword>Dapagliflozin</keyword>
  <keyword>Empagliflozin</keyword>
  <keyword>FMD</keyword>
  <keyword>T2DM</keyword>
  <keyword>Endothelial disfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

